Clinical trial · Interventional
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bevacizumab
- description
- Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Lung cancer symptom
- timeFrame
- Evaluated by lung cancer symptom scale 21-30 days after the treatment
Secondary outcomes (4)
- measure
- response rate
- timeFrame
- Evaluate response rate 21-30 days after the treatment
- measure
- Time to progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histological or cytological diagnosis of non-small cell lung cancer. 2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE) 3. Symptomatic MPE evaluated by researchers 4. Unsuitable for or reject systemic therapy of tumor 5. Estimated survival of more than 3 months. 6.18 years or older Exclusion Criteria: 1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants 2. Be allergic to bevacizumab 3. Pregnant or lactating woman 4. Pleural or pericardial infection
References
Publications (0)
Data not yet available